The development of multidrug resistance (MDR) to chemotherapy is a major obstacle for the successful treatment of cancer. A
number of mechanisms have been postulated to account for MDR in cancer. The most common and best-studied mechanism of resistance
is mediated through the drug efflux protein P-glycoprotein (P-gp), which is overexpressed in drug-resistant cancer cells and is responsible
for the removal of many chemotherapeutic agents. Therapeutic nanoparticles (NPs) have emerged as an innovative and promising option
to combat P-gp-mediated MDR and have shown enhanced therapeutic efficacy and reduced toxicity compared to their small molecule
counterparts. This review focuses on recent studies using therapeutic NPs to circumvent P-gp-mediated MDR in cancer therapy. The advantages
and strategies by which therapeutic NPs were used to overcome P-gp-mediated MDR in cancer are discussed.
Keywords: P-glycoprotein, multidrug resistance, nanotechnology, drug delivery, therapeutic nanoparticles, cancer chemotherapy.
Rights & PermissionsPrintExport